On 31 March 2026 the FDA’s Center for Drug Evaluation and Research issued warning letters to five websites selling injectable peptides to US buyers: Lovega LLC dba Pink Pony Peptides, Gram Peptides, Prime Sciences, Mile High Compounds and PekCura Labs. Each cites unapproved new drugs sold over the internet under sections 301(d) and 505(a) of the FD&C Act. Products carried coded names such as “GLP-2 TZ” and “GLP-3 RT”, which the quoted site copy identifies as tirzepatide and retatrutide; one firm listed cagrilintide and mazdutide outright. All five letters dismiss the sites’ research-use-only labelling, and each counts the bacteriostatic water sold alongside among the unapproved drug products.
Sources: FDA warning letter to Lovega LLC dba Pink Pony Peptides, 31 March 2026 · Gram Peptides, 31 March 2026 · Prime Sciences, 31 March 2026 · Mile High Compounds LLC, 31 March 2026 · PekCura Labs, 31 March 2026
